Home

Clinical trials

Search for a clinical trial

Filter

Geographical location

Type of cancer

Refine your search

Age

Phase

Search for a clinical trial

195 result(s)

Childhood and adolescent cancers
Paris
I3Y-MC-JPEH
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
ISABELLE AERTS GAJDOS
ENT/Head and Neck Cancers
Paris
219885 GALAXIES H&N-202
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
CHRISTOPHE LE TOURNEAU
Colorectal cancer
Saint-Cloud
ADAGE - Prodige 34
Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.
Cancers gynécologiques
Saint-Cloud
AFTERGYN
Optimize the Support of Patients in Pelvic Onco-gynecology Through Adapted Support Care in the Post-cancer Period. AFTERGYN Pilot Phase (AFTERGYN)
DIANA BELLO ROUFAI
Saint-Cloud
AIPAC
AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
ETIENNE BRAIN
Breast cancer
Paris, Saint-Cloud
ALCINA-4 (IC 2020-11)
Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4
LUC CABEL, FRANCOIS-CLEMENT BIDARD
Paris, Saint-Cloud
ALCYTA (IC 2020-12)
Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA
NICOLAS GIRARD
Saint-Cloud
ALPHABET
Randomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer
FRANCOIS-CLEMENT BIDARD
Saint-Cloud
AMEBICA - Prodige 38
Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours.
Saint-Cloud
AML LI-1
A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME
JACQUES VARGAFTIG
Saint-Cloud
APACaP
Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Eye tumors / Uveal melanoma
Paris
ATOM
Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study;(ATOM Trial)
MANUEL RODRIGUES
ENT/Head and Neck Cancers
Paris
AV-299-23-301
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)
CHRISTOPHE LE TOURNEAU
Saint-Cloud
AcSé Pembrolizumab
Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types.
CAROLE SOUSSAIN
Saint-Cloud
AcSé Vemurafenib
Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
ETIENNE BRAIN
Lung cancer
Paris
BAYER 22615 (SOHO 02)
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.
NICOLAS GIRARD
Sarcomas
Paris
BFR ESS 01
Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
SOPHIE PIPERNO-NEUMANN
Breast cancer
Paris
BGB-43395-101
Phase Ia/Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the CDK4 inhibitor BGB-43395 as monotherapy and in combination with other treatments in patients with HR+/HER2- metastatic breast cancer and other advanced solid tumors.
MARIE PAULE SABLIN
Paris
BGB-58067-101 (PRMT5i)
The BGB-58067-101 study is a Phase 1a/1b clinical trial evaluating BGB-58067, a selective MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors harboring homozygous MTAP deletion.
CHRISTOPHE LE TOURNEAU
Paris
BGB-A317-A3055-101
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors.
CHRISTOPHE LE TOURNEAU
Lung cancer
Paris
BI 1479-0008 (BEAMION LUNG 2)
Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled,;multi-centre trial evaluating orally administered;BI 1810631 compared with standard of care as first-line treatment;in patients with unresectable, locally advanced or metastatic nonsquamous;non-small cell lung cancer harbouring HER2 tyrosine;kinase domain mutations.
NICOLAS GIRARD
Bladder cancer
Paris
BLAD-RAD01 (GETUG-AFU V07)
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial.
GILLES CREHANGE
Saint-Cloud
BLOCAGE 01
Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line
CAROLE SOUSSAIN
ENT/Head and Neck Cancers
Paris
BNT113-01
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)
CHRISTOPHE LE TOURNEAU
Saint-Cloud
BO25430
AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY.
FLORENCE LEREBOURS
Breast cancer
Paris
BRAINSTORM
A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program
EDITH BORCOMAN
Saint-Cloud
BYLieve (CBYL719X402)
A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment
FLORENCE LEREBOURS
Leukemia
Saint-Cloud
Backbone Inter-Group-1 (BIG-1)
Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial
JACQUES VARGAFTIG
Lymphoma
Saint-Cloud
CA-4948-101
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphom.
CAROLE SOUSSAIN
Lymphoma
Saint-Cloud
CA073-1020
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
CLEMENTINE SARKOZY

1 2...7

Next >